

Oncology Today with Dr Neil Love
Dr. Neil Love
Medical oncologist Dr Neil Love interviews clinical investigators on new research and practical application to general medical oncology practice.
Episodes
Mentioned books

Nov 20, 2026 • 55min
GPRC5D-Directed Therapies for Multiple Myeloma — An Interview with Prof Rakesh Popat
Featuring an interview with Prof Rakesh Popat, including the following topics:Overview of GPRC5D and its clinical significance (0:00)Key findings from Phase II TALisman study regarding dysgeusia assessment for patients receiving talquetamab (2:30)Mitigating dysgeusia and dry mouth arising from GPRC5D-directed therapy (6:25)Key findings from the Phase III MonumenTAL-3 study (11:49)Selection factors for GPRC5D- and BCMA-directed therapies (15:16)Managing extramedullary multiple myeloma (MM) with GPRC5D-targeted therapies and beyond (18:30)Key findings with arlocabtagene autoleucel (arlo-cel) for relapsed/refractory (R/R) MM (20:47)Ramantamig and other GPRC5D-targeted approaches (25:32)Comparing arlo-cel to ciltacabtagene autoleucel for MM; CNS issues with GPRC5D-directed therapies (28:42)Case: A man in his late 70s with a history of chronic obstructive pulmonary disease and t(4;14) R/R MM who receives fourth-line talquetamab and attains a very good partial response (38:27)Cases: A man in his late 40s with t(11;14), del(17p) R/R MM who enrolls in the Phase II QUINTESSENTIAL-2 study for third-line treatment; a man in his late 60s with t(11;14), del(17p) MM and early relapse after third-line autologous stem cell transplant (45:18)Guidance on sequencing BCMA- and GPRC5D-directed therapies (47:35)Importance of tumor debulking; access to arlo-cel (52:27)CME information and select publications

Nov 16, 2026 • 16min
Novel Therapies for Non-Hodgkin Lymphoma — Microlearning Activity 3: An Interview with Dr Matthew Lunning on the Utility of Tafasitamab
Dr Matthew Lunning, a Fred and Pamela Buffett Cancer Center medical oncologist specializing in lymphoma, discusses tafasitamab across follicular lymphoma and diffuse large B-cell lymphoma. Topics include tafasitamab-lenalidomide versus epcoritamab, the FrontMIND trial, treatment considerations for frail or elderly patients, dosing, infection concerns, and CD19 antibody use before CAR T-cell therapy.

Nov 13, 2026 • 58min
Follicular Lymphoma — Where We Are, Where We're Headed in the Use of Bispecific Antibodies
Matthew Matasar, a Rutgers lymphoma specialist, and Chan Chea, an Australian hematology-oncology professor, explore the rapidly evolving role of bispecific antibodies in follicular lymphoma. They discuss T-cell engagement, second-line treatment, bispecifics versus CAR T, infection and neurologic complications, and promising agents such as surovatamig. The conversation also looks ahead to first-line therapy, multispecific antibodies, and next-generation immune strategies.

Nov 11, 2026 • 1h 2min
Relapsed/Refractory Multiple Myeloma — Proceedings from a Multitumor Symposium in Partnership with Florida Cancer Specialists & Research Institute
Sagar Lonial, a Winship myeloma specialist, and Paul G Richardson, a Dana-Farber therapeutics investigator, explore the fast-changing landscape of relapsed/refractory multiple myeloma. They discuss CAR T-cell therapy, bispecific antibodies, belantamab and other antibody-drug conjugates, treatment sequencing, resistance, aggressive extramedullary relapse, and emerging cereblon modulators in frontline and relapsed disease.

Nov 10, 2026 • 59min
Prostate Cancer — Proceedings from a Multitumor Symposium in Partnership with Florida Cancer Specialists & Research Institute
Emmanuel S Antonarakis, a University of Minnesota prostate cancer researcher, and Neeraj Agarwal, a Dana-Farber specialist in advanced disease, discuss modern treatment strategies. Topics include endocrine therapy, PARP inhibitors, AKT blockade for PTEN-deficient tumors, PSMA-targeted radiopharmaceuticals, MSI-high disease, and treatment choices after lutetium.

Nov 9, 2026 • 2h 22min
Breast Cancer — Proceedings from a Multitumor Symposium in Partnership with Florida Cancer Specialists & Research Institute
Charles E. Geyer Jr., Maryam Lustberg, Rita Nanda, and Seth Wander, leading breast cancer oncologists and researchers, explore major advances across ER-positive, HER2-positive, and triple-negative disease. Topics include oral SERDs, CDK4/6 inhibitors, ctDNA-guided care, ADC sequencing, HER2 treatment strategies, immunotherapy, and supportive care.

Nov 6, 2026 • 18min
Novel Therapies for Non-Hodgkin Lymphoma — Microlearning Activity 2: An Interview with Dr Matthew Lunning on Novel Combination Regimens
Dr Matthew Lunning, a lymphoma specialist and clinical investigator at the Fred and Pamela Buffett Cancer Center, explores cutting-edge treatment combinations for non-Hodgkin lymphoma. He discusses bispecific antibodies and antibody-drug conjugates in relapsed disease, options for patients avoiding CAR T-cell therapy, and treatment decisions for very elderly people with mantle cell lymphoma. The conversation also covers TP53 risk, blastoid disease, BCL2 combinations, and MRD-guided care.

Nov 4, 2026 • 1h 2min
Diffuse Large B-Cell Lymphoma — A Grand Rounds Program
Matthew Matasar, Chief of Blood Disorders at Rutgers Cancer Institute, explores evolving treatment strategies for diffuse large B-cell lymphoma. He discusses first-line choices, POLARIX and FrontMIND, plus the growing roles of CAR T-cell therapy, bispecific antibodies, and antibody-drug conjugates in relapsed disease. The conversation also covers treatment sequencing, CNS activity, cell-free DNA, and managing key toxicities.

Nov 2, 2026 • 18min
Novel Therapies for Non-Hodgkin Lymphoma — Microlearning Activity 1: An Interview with Dr Matthew Lunning on CNS Prophylaxis
Dr Matthew Lunning, a medical oncologist specializing in lymphoma and cellular therapy, discusses a high-risk DLBCL case in an older woman. Topics include pola-R-CHP, POLARIX and cell-of-origin testing, assessing CNS relapse risk, CSF evaluation, intrathecal methotrexate, and adapting treatment for frail adults. He also shares practical experience with the Polar Bear regimen.

Oct 29, 2026 • 1h 1min
Hormone Receptor-Positive Localized Breast Cancer — A Grand Rounds Activity
Dr Erica Mayer, a Dana-Farber medical oncologist and breast cancer investigator, explores personalized care for localized hormone receptor-positive breast cancer. Topics include genomic assays for chemotherapy decisions, late-recurrence testing, adjuvant CDK4/6 inhibitors, toxicity management, and emerging oral SERDs. She also addresses treatment selection, endocrine therapy intolerance, and the evolving role of genomic testing in neoadjuvant care.


